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Intravitreal injection is a treatment modality adopted widely 
in many diseases, including exudative age-related macular 
degeneration (AMD), retinal vein occlusion with macular 
edema, diabetic macular edema, proliferative diabetic reti-
nopathy (PDR) with vitreous hemorrhage, and choroidal neo-
vascularization secondary to various chorioretinal diseases 
including central serous chorioretinopathy. Intravitreal injec-
tions are reported to be administered 5.6 to 13 times per year 
on average in patients with AMD [1] and 5.8 times per year 
in those with diabetic retinopathy [2]. Moreover, the number 
of patients receiving intravitreal injections is increasing [3,4], 
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with most needing to receive continuous treatment to main-
tain the therapeutic efficacy. Many studies have sought to 
discern the best way to minimize the various potential side 
effects of intravitreal injections [5-7], but severe complica-
tions continue to appear, including endophthalmitis (0.3%), 
cataract (0.2-3.6%), and rhegmatogenous retinal detachment 
(RRD) (0.9%) [8-11]. Of critical importance in the injection 
process is to perform the injection at approximately 3.5 to 
4 mm from the limbus, given that penetration at more than 
4.5 mm from the limbus may damage the anterior base of 
the vitreous and ora serrata. Such trauma can cause severe 
damage to all layers of the retina, including retinal tears or 
holes, that can progress to vision-threatening conditions such 
as vitreous hemorrhage, RRD, and choroidal detachment [12]. 
Although there have been reports on the incidence of RRD 
after intravitreal injection, to our knowledge, there have 
been no studies performed only in Korean patients. Fur-
thermore, most studies that have included large numbers of 
participants have entailed the pooling of data from multiple 
centers with multiple physicians or are limited by a relatively 
small sample size of patients treated by a single physician [6]. 
In contrast, this study sought to report the incidence of RRD 
after intravitreal injections by a single physician in compari-
son with that reported previously and to describe the clinical 
features and outcomes in a large number of patients who 
received intravitreal injections from a single physician. 
Materials and Methods
The study was approved by the Institutional Review Board 
of Yonsei University Gangnam Severance Hospital (IRB No. 
3-2019-0283) and adhered to the tenets of the Declaration 
of Helsinki and the Good Clinical Practice guidelines. We 
retrospectively reviewed the medical records of patients who 
received intravitreal injections administered by a single ret-
inal specialist (M. K.) between February 2012 and January 
2019. Demographic data at baseline, including patient age 
and sex, and clinical data such as diagnoses, the number of 
intravitreal injections received, and the agent injected, were 
collected.
All patients provided written informed consent, which 
was documented electronically before each injection. The 
injection was administered in an operating room or a treat-
ment room in the outpatient clinic. A topical dilating agent 
(0.5% tropicamide/0.5% phenylephrine, Tropherine®; Hanmi 
Pharm Co. Ltd., Seoul, Korea) was administered 30 minutes 
before injection. Additionally, topical 0.5% proparacaine 
hydrochloride (Alcaine®; Alcon, Fort Worth, TX, USA) was 
instilled in the eye before each injection, followed by appli-
cation of a povidone-iodine swab to the eyelid, eyelashes, 
and lid margin. A sterile speculum was inserted, and 5% 
povidone-iodine solution was introduced over the ocular 
surface to sterilize the conjunctival sac. The intravitreal 
injection was performed at 3.5 to 4.0 mm from the limbus, 
mainly in the superotemporal or inferotemporal quadrant. A 
30-gauge needle was used for all injections, except those in-
volving Ozurdex® (Allergan Inc., Dublin, Ireland), for which 
an enclosed 22-gauge needle was used. All patients received 
topical 0.3% gatifloxacin (Gatiflo®; Handok, Seoul, Korea) 
for one week after each injection [6,7,13].
Patients were followed up at one month after each injec-
tion. All patients underwent a fundus examination including 
ultra-widefield scanning laser ophthalmoscopy (Optomap; 
Optos, Marlborough, MA, USA) and dilated binocular in-
direct ophthalmoscopy at each visit. Patients were provided 
with verbal and written instructions to visit the clinic earlier 
or to contact a local ophthalmologist if they developed sudden 
floaters, flashes, a visual field defect, loss of vision, eye pain, 
or redness. Patients presenting to our clinic with such symp-
toms were examined immediately. Patients with less than 
three months of follow-up data after treatment were excluded.
All fundus images, time of occurrence, features of the 
condition, and the course of treatment were reviewed if RRD 
developed after intravitreal injection. All statistical analyses 
were performed using the Statistical Package for the Social 
Sciences for Windows (version 23.0; IBM Corp., Armonk, 
NY, USA).
Results
A total of 9,484 injections was performed in 1,739 eyes of 
1,480 patients. The mean patient age at the time of the first 
injection was 59.7 ± 17.6 (range, 0-94) years, and 842 pa-
tients (56.9%) were male. The mean follow-up duration was 
26.3 ± 19.3 (range, 3.0-82.0) months (Table 1). The average 
number of injections per eye was 5.3 ± 6.5 (range, 1-46). The 
agents injected were as follows: bevacizumab (Avastin®; 
Genentech Inc., San Francisco, CA, USA) in 5,766 (60.8%); 
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aflibercept (Eylea®; Bayer, Leverkusen, Germany) in 1,603 
(16.9%); ranibizumab (Lucentis®; Genentech Inc.) in 1,385 
(14.6%); dexamethasone intravitreal implant (Ozurdex®; Al-
lergan, Inc.) in 654 (6.9%); and others (including ganciclovir 
[Cymevene®; Hoffmann-La Roche, Welwyn Garden City, 
UK], steroids, antibiotics, and antifungals) in 76 (0.8%) (Ta-
ble 1).
The most common condition requiring intravitreal in-
jection was exudative AMD (n = 353, 23.9%), which was 
followed by vitreous hemorrhage associated with diabetic 
retinopathy (n = 286; 19.3%), retinal vein occlusion with 
macular edema (n = 221, 14.9%), diabetic macular edema 
(n = 169, 11.4%), central serous chorioretinopathy (n = 146, 
9.9%), and uveitis (n = 89, 6.0%) (Table 2).
The occurrence of RRD was noted as a complication in 
only one eye from one patient, yielding incidence rates of 
0.01% per injection and 0.06% per injected eye. This com-
plication occurred in a 36-year-old man with a diagnosis of 
PDR accompanied by vitreous hemorrhage in his left eye 
who received three consecutive intravitreal injections of 
bevacizumab. He was scheduled to return for an outpatient 
follow-up visit at one month after the final injection but ex-
perienced sudden vision loss in the treated eye after only two 
weeks. Dilated fundus examination revealed a peripheral 
retinal tear at the superotemporal quadrant with bullous ret-
inal detachment in the temporal half of the retina involving 
the macula (Fig. 1). The patient underwent prompt vitrecto-
my with gas tamponade. During subsequent postoperative 
follow-up, the patient remained stable without complications, 
such as recurrence of RRD, or need for additional injections 
or other treatment.
Table 1. Baseline characteristics of the study population
Characteristic Value
Total number of injections performed 9,484
Total number of subjects/eyes 1,480/1,739
Age at time of first injection (years) 59.7 ± 17.6
Sex (male) 842 (56.9)




Dexamethasone implant 654 (6.9)
Other (antibacterial, antiviral, or antifungal) 76 (0.8)
Follow-up duration (months) 26.3 ± 19.3
Values are presented as mean ± standard deviation or number (%).
Table 2. Diagnoses of patients treated with intravitreal injections
Diagnose Value
Neovascular age-related macular degeneration 353 (23.9)
P roliferative diabetic retinopathy with vitreous 
hemorrhage
286 (19.3)
Retinal vein occlusion with macular edema 221 (14.9)
Diabetic macular edema 169 (11.4)
Central serous chorioretinopathy 146 (9.9)
Uveitis (including uveitic macular edema) 89 (6.0)
Retinopathy of prematurity 33 (2.2)
Cytomegalovirus retinitis 22 (1.5)
Hypertensive retinopathy 9 (0.6)
Retinal vasculitis 6 (0.4)









Figure 1. Retinal detachment after intravitreal injection of anti-vas-
cular endothelial growth factor in a 36-year-old man diagnosed 
with proliferative diabetic retinopathy accompanied by vitreous 
hemorrhage in his left eye. (A) A wide-field fundus image acquired 
before intravitreal bevacizumab injection shows residual vitreous 
hemorrhage without peripheral retinal breaks. (B) Two weeks after 
intravitreal bevacizumab injection, a bullous retinal detachment 
was evident. (C) After prompt vitrectomy, a well-attached retina can 
be seen at one month postoperatively. (D) Follow-up imaging at 
18 months after surgery revealed a stable flat retina with peripheral 





In the present retrospective review of 9,484 intravitreal injec-
tions performed by a single retinal specialist, we identified 
only one case complicated by RRD among 1,739 eyes from 
1,480 patients, for an incidence rate of 0.01% per injection. 
According to previous studies, the incidence of RRD after 
intravitreal injection varies from 0% to 0.9% [6,7,9,14-20]. 
The incidence in our study, which is based on a relatively 
large number of cases, was significantly lower than that in 
previous reports. This discrepancy may reflect differences in 
study design such as number of physicians involved, periop-
erative procedures, and the treating physician’s proficiency 
and technique.
Park et al. [21] reported that 10.39 cases of RRD per 
100,000 people in South Korea occurred from 2007 to 2011, 
which is an incidence of 0.01%. This rate is similar to that 
in our study, suggesting that intravitreal injection does not 
necessarily increase the risk of RRD compared to its inci-
dence in the general population if appropriate perioperative 
management protocols and injection techniques are used. 
However, it is difficult to exclude the risk of retinal detach-
ment after intravitreal injection, especially given that all 
intravitreal injections were administered by the same physi-
cian in our study and the variable incidence rates reported in 
previous research [6].
Adopting the correct injection technique is critical to 
minimizing the risk of serious complications. A crucial step 
in reducing the incidence of RRD may be identifying the 
correct anatomic location for injection. If the needle were to 
penetrate posterior to the appropriate site, the anterior base 
of the vitreous and ora serrata could be damaged, and the 
entire retina could be breached. Such damage can lead to 
retinal tears and progress to retinal detachment [22]. There-
fore, to minimize the risk of RRD, physicians should avoid 
the anterior base of the vitreous and ora serrata by targeting 
the area 3.5 to 4.0 mm from the corneolimbal margin and, at 
the same time, should not point the tip of the needle too far 
posteriorly. Furthermore, to avoid complications such as vit-
reous incarceration, the sclera should be penetrated obliquely 
rather than perpendicularly. Indeed, there are reports that a 
double-plane tunnel technique can significantly lower the 
risk of RRD. Using this technique, the sclera is first penetrat-
ed at an angle of 15° to 30°, after which point, the needle is 
repositioned to an angle of 45° to 60° while the sclera is still 
engaged [22-24].
The RRD case in our study occurred in a male patient 
with myopia (-5.25 diopters) who was treated with three 
consecutive intravitreal bevacizumab injections prior to 
occurrence of RRD. A previous study by Meyer et al. [7] re-
ported a higher incidence of RRD in myopic eyes, with four 
of the five RRD cases having myopia ranging from -1.75 to 
-5.5 diopters. The authors recommended examining myo-
pic eyes for lattice degeneration, atrophic holes, or vitreous 
tractions with a contact lens and treating these lesions prior 
to proceeding with a patient’s first injection. Although no 
definite retinal tear or lattice degeneration was found prior to 
injection in our case, a careful fundus examination including 
a contact lens exam may help to prevent post-injection RRD 
in myopic eyes. Furthermore, the indication for treatment 
in this particular patient was PDR. The natural course of 
PDR is a cycle of proliferation and regression of new vessels, 
proliferation of fibrous tissue, adhesion between the poste-
rior vitreous surface and fibrovascular proliferations, and 
contraction of the posterior vitreous. Intravitreous injection 
of bevacizumab could perhaps worsen this natural course by 
stimulating regression of the vascular component of fibro-
vascular proliferation with a concurrent increase in fibrosis, 
eventually aggravating the retinal traction [25]. As this so-
called “crunch syndrome” is a well-known contributing 
factor to tractional retinal detachment, injections should be 
performed only after careful deliberation in patients with 
PDR.
Our study population included diseases like acute retinal 
necrosis and cytomegalovirus retinitis that tend to pair with 
a high incidence of retinal tear. In these conditions, a hole or 
tear can form in the necrotic area due to disease progression 
regardless of intravitreal injection. However, in our study, 
there was no patient who presented with retinal tear or ret-
inal hole. The small number of patients with these diseases 
seems to have influenced the results.
Our study has several limitations. First, all the patients en-
rolled were from the practice of one retinal specialist at a sin-
gle tertiary hospital. Second, there was only one confirmed 
case of RRD as a complication, which made it difficult to 
determine whether or not the risk of RRD depends on injec-
tion site, agent injected, or another factor such as the disease 
being treated. Therefore, further research to answer these 
questions is needed in the future. However, the strength of 
our study is that it is a single-center, single-practitioner case 
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series with a relatively long follow-up period that included 
a larger number of patients than in previous studies, which 
allowed us to minimize the variations introduced by multiple 
practitioners.
The incidence of RRD after intravitreal injection in our 
study was similar to that reported in previous studies and to 
the overall incidence of RRD in the Korean population. This 
finding suggests that intravitreal injection is a safe treatment 
modality when performed with a proper technique and safe-
ty precautions. 
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